Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS).

Purpose: On November 28, 2023, the U.S. FDA issued a Drug Safety Communication, warning that antiseizure medications (ASMs) levetiracetam and clobazam can cause a rare but serious reaction, drug reaction with eosinophilia and systemic symptoms (DRESS).

Public Health.

Background: Prior research identified delays in diagnosis of Amyotrophic Lateral Sclerosis (ALS) amongst ethnic and racial minorities. This study examined differences in diagnostic delays and symptom severity between White non-Hispanic and Hispanic/Latinx patients.

Method: To increase the number of Hispanic/Latinx cases, data from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT), a database including clinical trial participants from nine contributing entities, were combined with a sample of patients recruited from the multidisciplinary ALS clinic at UT Health San Antonio.

Cancer Incidence Among People With a Prior Hospital Record of Depression in Scotland, 1991-2019: A Cohort Study.

Objective: Current evidence on the association between depression and cancer risk is conflicting, with little understanding of how associations vary by time period or sociodemographic factors. We aimed to compare cancer incidence in people with versus without a previous hospital admission record for depression, by sociodemographic factors and over time.

Methods: We conducted a cohort study using national linked data in Scotland from 1991 to 2019.

COA5 has an essential role in the early stage of mitochondrial complex IV assembly.

Pathogenic variants in cytochrome oxidase assembly factor 5 (COA5), a proposed complex IV (CIV) assembly factor, have been shown to cause clinical mitochondrial disease with two siblings affected by neonatal hypertrophic cardiomyopathy manifesting a rare, homozygous missense variant (NM_001008215.3: c.157G>C, p.